124 related articles for article (PubMed ID: 26950705)
1. Anticoagulant Effect of Sugammadex: Just an In Vitro Artifact.
Dirkmann D; Britten MW; Pauling H; Weidle J; Volbracht L; Görlinger K; Peters J
Anesthesiology; 2016 Jun; 124(6):1277-85. PubMed ID: 26950705
[TBL] [Abstract][Full Text] [Related]
2. Interactions of sugammadex with various anticoagulants
.
Kruithof AC; Kluft C; de Kam PJ; Laterveer GH; Moerland M; Burggraaf J
Int J Clin Pharmacol Ther; 2020 Jul; 58(7):395-403. PubMed ID: 32383642
[TBL] [Abstract][Full Text] [Related]
3. Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.
De Kam PJ; Grobara P; Prohn M; Höppener F; Kluft C; Burggraaf J; Langdon RB; Peeters P
Int J Clin Pharmacol Ther; 2014 Mar; 52(3):227-36. PubMed ID: 24447651
[TBL] [Abstract][Full Text] [Related]
4. A PK-PD model-based assessment of sugammadex effects on coagulation parameters.
Bosch R; van Lierop MJ; de Kam PJ; Kruithof AC; Burggraaf J; de Greef R; Visser SA; Johnson-Levonas AO; Kleijn HJ
Eur J Pharm Sci; 2016 Mar; 84():9-17. PubMed ID: 26747019
[TBL] [Abstract][Full Text] [Related]
5. Lack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects.
De Kam PJ; Kruithof AC; van Lierop MJ; Moerland M; Dennie J; Troyer MD; Langdon RB; Gutstein DE; Burggraaf J; El Galta R
Int J Clin Pharmacol Ther; 2014 Aug; 52(8):631-41. PubMed ID: 24800921
[TBL] [Abstract][Full Text] [Related]
6. The mode of action of sugammadex on coagulation.
Kruithof AC; Kluft C; de Kam PJ; Laterveer RH; Moerland M; Burggraaf J
Int J Clin Pharmacol Ther; 2021 Feb; 59(2):89-98. PubMed ID: 33155541
[TBL] [Abstract][Full Text] [Related]
7. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant.
Mani H; Herth N; Kasper A; Wendt T; Schuettfort G; Weil Y; Pfeilschifter W; Linnemann B; Herrmann E; Lindhoff-Last E
Ther Drug Monit; 2014 Oct; 36(5):624-31. PubMed ID: 24577124
[TBL] [Abstract][Full Text] [Related]
8. Presence of direct thrombin inhibitors can affect the results and interpretation of lupus anticoagulant testing.
Genzen JR; Miller JL
Am J Clin Pathol; 2005 Oct; 124(4):586-93. PubMed ID: 16146819
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban demonstrates in vitro anticoagulant effects in canine plasma.
Conversy B; Blais MC; Dunn M; Gara-Boivin C; Carioto L; del Castillo JR
Vet J; 2013 Nov; 198(2):437-43. PubMed ID: 24053991
[TBL] [Abstract][Full Text] [Related]
10. Standardization of coagulation tests.
Opartkiattikul N
Southeast Asian J Trop Med Public Health; 1999; 30 Suppl 3():79-85. PubMed ID: 10926265
[TBL] [Abstract][Full Text] [Related]
11. In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry.
Tanaka KA; Szlam F; Rusconi CP; Levy JH
Thromb Haemost; 2009 May; 101(5):827-33. PubMed ID: 19404534
[TBL] [Abstract][Full Text] [Related]
12. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
[TBL] [Abstract][Full Text] [Related]
13. Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.
Gaussem P; Dubar M; le Bonniec B; Richard-Lordereau I; Jochemsen R; Aiach M
Br J Clin Pharmacol; 2002 Feb; 53(2):147-54. PubMed ID: 11851638
[TBL] [Abstract][Full Text] [Related]
14. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays.
Lindahl TL; Baghaei F; Blixter IF; Gustafsson KM; Stigendal L; Sten-Linder M; Strandberg K; Hillarp A;
Thromb Haemost; 2011 Feb; 105(2):371-8. PubMed ID: 21103660
[TBL] [Abstract][Full Text] [Related]
15. Dexamethasone produces dose-dependent inhibition of sugammadex reversal in in vitro innervated primary human muscle cells.
Rezonja K; Sostaric M; Vidmar G; Mars T
Anesth Analg; 2014 Apr; 118(4):755-63. PubMed ID: 24651229
[TBL] [Abstract][Full Text] [Related]
16. Amphipathic peptides can act as an anticoagulant by competing with phospholipid membranes for blood coagulation factors.
Charbonneau S; Peng HT; Shek PN; Blostein MD
Biochem Biophys Res Commun; 2010 Jan; 391(2):1197-202. PubMed ID: 20005198
[TBL] [Abstract][Full Text] [Related]
17. Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate.
Douxfils J; Mullier F; Robert S; Chatelain C; Chatelain B; Dogné JM
Thromb Haemost; 2012 May; 107(5):985-97. PubMed ID: 22438031
[TBL] [Abstract][Full Text] [Related]
18. Effect of reversal of neuromuscular blockade with sugammadex versus usual care on bleeding risk in a randomized study of surgical patients.
Rahe-Meyer N; Fennema H; Schulman S; Klimscha W; Przemeck M; Blobner M; Wulf H; Speek M; McCrary Sisk C; Williams-Herman D; Woo T; Szegedi A
Anesthesiology; 2014 Nov; 121(5):969-77. PubMed ID: 25208233
[TBL] [Abstract][Full Text] [Related]
19. Performance of Platelin LS and dilute Russell's viper venom for the screening of lupus anticoagulant in patients with venous thromboembolism.
Morelli VM; Rodrigues CA; Noguti MA; Matos MF; da Silveira RC; Ribeiro AA; Lourenço DM
Blood Coagul Fibrinolysis; 2007 Jul; 18(5):401-5. PubMed ID: 17581313
[TBL] [Abstract][Full Text] [Related]
20. Thromboelastometric (ROTEM) findings in patients suffering from isolated severe traumatic brain injury.
Schöchl H; Solomon C; Traintinger S; Nienaber U; Tacacs-Tolnai A; Windhofer C; Bahrami S; Voelckel W
J Neurotrauma; 2011 Oct; 28(10):2033-41. PubMed ID: 21942848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
